Journal
Journal of Clinical Oncology
Publication Date
5-20-2024
Volume
42
Issue
15
First Page
1766
Last Page
1775
Document Type
Open Access Publication
DOI
10.1200/JCO.23.02474
Rights and Permissions
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. © 2024 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended Citation
Levis, Mark J; Uy, Geoffrey L; and et al., "Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3." Journal of Clinical Oncology. 42, 15. 1766 - 1775. (2024).
https://digitalcommons.wustl.edu/oa_4/4075
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
